CN109777870A - 一种用于指导人精神疾病用药的试剂盒及其检测方法 - Google Patents
一种用于指导人精神疾病用药的试剂盒及其检测方法 Download PDFInfo
- Publication number
- CN109777870A CN109777870A CN201910168662.2A CN201910168662A CN109777870A CN 109777870 A CN109777870 A CN 109777870A CN 201910168662 A CN201910168662 A CN 201910168662A CN 109777870 A CN109777870 A CN 109777870A
- Authority
- CN
- China
- Prior art keywords
- seq
- kit
- follows
- extension
- sap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 229940079593 drug Drugs 0.000 title claims abstract description 54
- 238000001514 detection method Methods 0.000 title claims abstract description 42
- 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 27
- 230000002068 genetic effect Effects 0.000 claims abstract description 17
- 230000035772 mutation Effects 0.000 claims abstract description 11
- 101150076401 16 gene Proteins 0.000 claims abstract description 10
- 239000012634 fragment Substances 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 230000003321 amplification Effects 0.000 claims description 15
- 108010000178 IGF-I-IGFBP-3 complex Proteins 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 8
- 102220197630 rs1041983 Human genes 0.000 claims description 8
- 102200026593 rs1065852 Human genes 0.000 claims description 8
- 102200026617 rs1135840 Human genes 0.000 claims description 8
- 102200094900 rs1799930 Human genes 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000005498 polishing Methods 0.000 claims description 5
- 230000036425 denaturation Effects 0.000 claims description 4
- 238000004925 denaturation Methods 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 18
- 238000005516 engineering process Methods 0.000 abstract description 17
- 238000012163 sequencing technique Methods 0.000 abstract description 16
- 238000007403 mPCR Methods 0.000 abstract description 5
- 238000001819 mass spectrum Methods 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 55
- 238000012360 testing method Methods 0.000 description 29
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 229960002073 sertraline Drugs 0.000 description 15
- 238000003205 genotyping method Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 12
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 12
- 230000036651 mood Effects 0.000 description 11
- 230000007958 sleep Effects 0.000 description 11
- 102000019057 Cytochrome P-450 CYP2C19 Human genes 0.000 description 9
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 229960003120 clonazepam Drugs 0.000 description 8
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 201000000980 schizophrenia Diseases 0.000 description 8
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 7
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 7
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 7
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 7
- 229960005017 olanzapine Drugs 0.000 description 7
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 7
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 7
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 7
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 6
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 6
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 5
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000009514 concussion Effects 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 229960004431 quetiapine Drugs 0.000 description 5
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 5
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 4
- 101000783617 Homo sapiens 5-hydroxytryptamine receptor 2A Proteins 0.000 description 4
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 4
- 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 description 4
- 102100023724 Melanocortin receptor 4 Human genes 0.000 description 4
- 102100037026 Peptidyl-prolyl cis-trans isomerase FKBP5 Human genes 0.000 description 4
- 102100029633 UDP-glucuronosyltransferase 2B15 Human genes 0.000 description 4
- 101710200683 UDP-glucuronosyltransferase 2B15 Proteins 0.000 description 4
- 229960004538 alprazolam Drugs 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000004630 mental health Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 101100397240 Arabidopsis thaliana ISPD gene Proteins 0.000 description 3
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 239000011093 chipboard Substances 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960004606 clomipramine Drugs 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 3
- 229960001785 mirtazapine Drugs 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000004089 psychotropic agent Substances 0.000 description 3
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 3
- 229940035004 seroquel Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- BGZSGIQMFUUNPT-UHFFFAOYSA-N C(CC)OC(CCCC)=O.[Mg] Chemical compound C(CC)OC(CCCC)=O.[Mg] BGZSGIQMFUUNPT-UHFFFAOYSA-N 0.000 description 2
- 206010027940 Mood altered Diseases 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940096383 olanzapine 5 mg Drugs 0.000 description 2
- 238000011022 operating instruction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940051280 sertraline 150 mg Drugs 0.000 description 2
- 229960003660 sertraline hydrochloride Drugs 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 108010000410 MSH receptor Proteins 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- YGULWPYYGQCFMP-CEAXSRTFSA-N Metoprolol tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 YGULWPYYGQCFMP-CEAXSRTFSA-N 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042345 Subcutaneous haematoma Diseases 0.000 description 1
- -1 Xi De Chemical compound 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940054157 lexapro Drugs 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000008836 maxillary sinusitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940106761 mirtazapine 15 mg Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940080131 olanzapine 10 mg Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229940071979 sertraline 100 mg Drugs 0.000 description 1
- 229940071981 sertraline 50 mg Drugs 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6872—Methods for sequencing involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
基因位点 | 上游引物5’-3’ | 下游引物5’-3’ |
rs1041983 | No.1:ACGTTGGATGAGACCACAATGTTAGGAGGG | No.2:ACGTTGGATGCAGGAGAAGGTGAACCATGC |
rs1058164 | No.3:ACGTTGGATGGTGTTCCTGGCGCGCTATG | No.4:ACGTTGGATGACTGCTCCAGCGACTTCTTG |
rs1065852 | No.5:ACGTTGGATGTGGTGGACCTGATGCACCG | No.6:ACGTTGGATGAGTCCACATGCAGCAGGTTG |
rs1079597 | No.7:ACGTTGGATGATACATGATCCTAAGGGCAG | No.8:ACGTTGGATGTCCACAGTGCTGTCAGAATC |
rs1135840 | No.9:ACGTTGGATGACTAGGTACCCCATTCTAGC | No.10:ACGTTGGATGCCATGGTGTCTTTGCTTTCC |
rs1360780 | No.11:ACGTTGGATGAGGCACAGAAGGCTTTCACA | No.12:ACGTTGGATGTGCCAGCAGTAGCAAGTAAG |
rs1799930 | No.13:ACGTTGGATGTGGAGACGTCTGCAGGTATG | No.14:ACGTTGGATGCCTGCCAAAGAAGAAACACC |
rs1799978 | No.15:ACGTTGGATGTTTTGAGGCGGGAACGCAAC | No.16:ACGTTGGATGAGGACCCAGCCTGCAATCA |
rs1800497 | No.17:ACGTTGGATGACACAGCCATCCTCAAAGTG | No.18:ACGTTGGATGTGTGCAGCTCACTCCATCCT |
rs1902023 | No.19:ACGTTGGATGCCATCTATCGAGAATTTTCAG | No.20:ACGTTGGATGCAATGCCAGTAAATCATCTGC |
rs2069514 | No.21:ACGTTGGATGATCTTGGCTCACCGCAACCT | No.22:ACGTTGGATGTGGTGCACACCTGTAATTCC |
rs4244285 | No.23:ACGTTGGATGCACTTTCCATAAAAGCAAGG | No.24:ACGTTGGATGGCAATAATTTTCCCACTATC |
rs489693 | No.25:ACGTTGGATGCCAGATTTGGTCAATACAGG | No.26:ACGTTGGATGATACCTGCCACGCTGTAAAC |
rs762551 | No.27:ACGTTGGATGCTAAGCTCCATCTACCATGC | No.28:ACGTTGGATGGAATCTTGAGGCTCCTTTCC |
rs776746 | No.29:ACGTTGGATGCAGCTTAACGAATGCTCTAC | No.30:ACGTTGGATGGTAATGTGGTCCAAACAGGG |
rs7997012 | No.31:ACGTTGGATGCTTTCTTAGTGACATTTGCC | No.32:ACGTTGGATGCCTTCCAAGAATCCTGGATG |
基因位点 | 上游引物5’-3’ | 下游引物5’-3’ |
rs1041983 | No.1:ACGTTGGATGAGACCACAATGTTAGGAGGG | No.2:ACGTTGGATGCAGGAGAAGGTGAACCATGC |
rs1058164 | No.49:ACGTTGGATGATCACCCACCGGAGTGGTT | No.50:ACGTTGGATGGGAGACCAGGGGGAGCAT |
rs1065852 | No.5:ACGTTGGATGTGGTGGACCTGATGCACCG | No.6:ACGTTGGATGAGTCCACATGCAGCAGGTTG |
rs1079597 | No.7:ACGTTGGATGATACATGATCCTAAGGGCAG | No.8:ACGTTGGATGTCCACAGTGCTGTCAGAATC |
rs1135840 | No.9:ACGTTGGATGACTAGGTACCCCATTCTAGC | No.10:ACGTTGGATGCCATGGTGTCTTTGCTTTCC |
rs1360780 | No.11:ACGTTGGATGAGGCACAGAAGGCTTTCACA | No.12:ACGTTGGATGTGCCAGCAGTAGCAAGTAAG |
rs1799930 | No.13:ACGTTGGATGTGGAGACGTCTGCAGGTATG | No.14:ACGTTGGATGCCTGCCAAAGAAGAAACACC |
rs1799978 | No.15:ACGTTGGATGTTTTGAGGCGGGAACGCAAC | No.16:ACGTTGGATGAGGACCCAGCCTGCAATCA |
rs1800497 | No.51:ACGTTGGATGACATGATGCCCTGCTTTCGG | No.52:ACGTTGGATGACACAGCCATCCTCAAAGTG |
rs1902023 | No.19:ACGTTGGATGCCATCTATCGAGAATTTTCAG | No.20:ACGTTGGATGCAATGCCAGTAAATCATCTGC |
rs2069514 | No.53:ACGTTGGATGTTGAGACAGAATCTTGCTCT | No.54:ACGTTGGATGGAAGCTGGGGCATGACAATT |
rs4244285 | No.23:ACGTTGGATGCACTTTCCATAAAAGCAAGG | No.24:ACGTTGGATGGCAATAATTTTCCCACTATC |
rs489693 | No.25:ACGTTGGATGCCAGATTTGGTCAATACAGG | No.26:ACGTTGGATGATACCTGCCACGCTGTAAAC |
rs762551 | No.27:ACGTTGGATGCTAAGCTCCATCTACCATGC | No.28:ACGTTGGATGGAATCTTGAGGCTCCTTTCC |
rs776746 | No.29:ACGTTGGATGCAGCTTAACGAATGCTCTAC | No.30:ACGTTGGATGGTAATGTGGTCCAAACAGGG |
rs7997012 | No.31:ACGTTGGATGCTTTCTTAGTGACATTTGCC | No.32:ACGTTGGATGCCTTCCAAGAATCCTGGATG |
SAP缓冲液 | 0.17μL CutSmart buffer(生产商NEB) |
SAP酶 | 0.5U(生产商NEB) |
水 | 补齐至2μL |
Klenow酶缓冲液 | 0.2μL(产自NEB,缓冲液2) |
Klenow酶 | 1U(产自NEB) |
延伸引物混合液 | 0.94μL |
反应终止液 | 0.2μL(产自NEB) |
纯水 | 补齐至2μL |
SNP_ID | 最佳比例 | 低 | 高 |
rs1041983 | 1.66 | 1.65 | 1.69 |
rs1058164 | 2.73 | 2.72 | 2.75 |
rs1065852 | 1.00 | 0.98 | 1.02 |
rs1079597 | 1.39 | 1.38 | 1.41 |
rs1135840 | 1.48 | 1.46 | 1.50 |
rs1360780 | 1.56 | 1.55 | 1.58 |
rs1799930 | 1.55 | 1.53 | 1.57 |
rs1799978 | 1.79 | 1.77 | 1.81 |
rs1800497 | 1.50 | 1.48 | 1.51 |
rs1902023 | 1.85 | 1.84 | 1.88 |
rs2069514 | 1.16 | 1.15 | 1.19 |
rs4244285 | 1.73 | 1.70 | 1.74 |
rs489693 | 2.12 | 2.10 | 2.13 |
rs762551 | 1.19 | 1.17 | 1.20 |
rs776746 | 1.70 | 1.69 | 1.72 |
rs7997012 | 1.84 | 1.82 | 1.86 |
基因位点 | 上游引物5’-3’ | 下游引物5’-3’ |
rs1041983 | No.1:ACGTTGGATGAGACCACAATGTTAGGAGGG | No.2:ACGTTGGATGCAGGAGAAGGTGAACCATGC |
rs1058164 | No.3:ACGTTGGATGGTGTTCCTGGCGCGCTATG | No.4:ACGTTGGATGACTGCTCCAGCGACTTCTTG |
rs1065852 | No.5:ACGTTGGATGTGGTGGACCTGATGCACCG | No.6:ACGTTGGATGAGTCCACATGCAGCAGGTTG |
rs1079597 | No.7:ACGTTGGATGATACATGATCCTAAGGGCAG | No.8:ACGTTGGATGTCCACAGTGCTGTCAGAATC |
rs1135840 | No.9:ACGTTGGATGACTAGGTACCCCATTCTAGC | No.10:ACGTTGGATGCCATGGTGTCTTTGCTTTCC |
rs1360780 | No.11:ACGTTGGATGAGGCACAGAAGGCTTTCACA | No.12:ACGTTGGATGTGCCAGCAGTAGCAAGTAAG |
rs1799930 | No.13:ACGTTGGATGTGGAGACGTCTGCAGGTATG | No.14:ACGTTGGATGCCTGCCAAAGAAGAAACACC |
rs1799978 | No.15:ACGTTGGATGTTTTGAGGCGGGAACGCAAC | No.16:ACGTTGGATGAGGACCCAGCCTGCAATCA |
rs1800497 | No.17:ACGTTGGATGACACAGCCATCCTCAAAGTG | No.18:ACGTTGGATGTGTGCAGCTCACTCCATCCT |
rs1902023 | No.19:ACGTTGGATGCCATCTATCGAGAATTTTCAG | No.20:ACGTTGGATGCAATGCCAGTAAATCATCTGC |
rs2069514 | No.53:ACGTTGGATGTTGAGACAGAATCTTGCTCT | No.54:ACGTTGGATGGAAGCTGGGGCATGACAATT |
rs4244285 | No.23:ACGTTGGATGCACTTTCCATAAAAGCAAGG | No.24:ACGTTGGATGGCAATAATTTTCCCACTATC |
rs489693 | No.25:ACGTTGGATGCCAGATTTGGTCAATACAGG | No.26:ACGTTGGATGATACCTGCCACGCTGTAAAC |
rs762551 | No.27:ACGTTGGATGCTAAGCTCCATCTACCATGC | No.28:ACGTTGGATGGAATCTTGAGGCTCCTTTCC |
rs776746 | No.29:ACGTTGGATGCAGCTTAACGAATGCTCTAC | No.30:ACGTTGGATGGTAATGTGGTCCAAACAGGG |
rs7997012 | No.31:ACGTTGGATGCTTTCTTAGTGACATTTGCC | No.32:ACGTTGGATGCCTTCCAAGAATCCTGGATG |
SNP_ID | 延伸引物 |
rs1041983 | No.33:CAATGTTAGGAGGGTATTTTTA |
rs1058164 | No.57:GTTGCGCAAGGTGGA |
rs1065852 | No.35:TGGGCTGCACGCTAC |
rs1079597 | No.36:TGTGATCAGATTCGCCTTT |
rs1135840 | No.56:GGTTTGCTTTCCTGGTGA |
rs1360780 | No.38:GCTTTCACATAAGCAAAGTTA |
rs1799930 | No.39:GACTCAAAATCTTCAATTGTT |
rs1799978 | No.40:CCCCCCACACCCAGAGTAA |
rs1800497 | No.58:GGGCTGGGCGCCTGCCT |
rs1902023 | No.42:ATTTGCAGAAGAGAATCTTCCAAAT |
rs2069514 | No.43:GTCAACCTCCGCCTCTC |
rs4244285 | No.44:GTAAGTAATTTGTTATGGGTTCC |
rs489693 | No.45:CCCATTCTGTTGTCATTAGTTCC |
rs762551 | No.46:ATCTACCATGCGTCCTG |
rs776746 | No.47:TTACAGAGCTCTTTTGTCTTTCA |
rs7997012 | No.48:TGCCATTATCTTCAAAGACTTAATT |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/124304 WO2020177433A1 (zh) | 2018-11-07 | 2019-12-10 | 一种用于指导人精神疾病用药的试剂盒及其检测方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811318666.6A CN109234383A (zh) | 2018-11-07 | 2018-11-07 | 与抗精神疾病药相关的试剂盒、目标基因及其制备、snp标记、snp识别和应用 |
CN2018113186666 | 2018-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109777870A true CN109777870A (zh) | 2019-05-21 |
CN109777870B CN109777870B (zh) | 2019-10-29 |
Family
ID=65077156
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811318666.6A Pending CN109234383A (zh) | 2018-11-07 | 2018-11-07 | 与抗精神疾病药相关的试剂盒、目标基因及其制备、snp标记、snp识别和应用 |
CN201910168662.2A Active CN109777870B (zh) | 2018-11-07 | 2019-03-06 | 一种用于指导人精神疾病用药的试剂盒及其检测方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811318666.6A Pending CN109234383A (zh) | 2018-11-07 | 2018-11-07 | 与抗精神疾病药相关的试剂盒、目标基因及其制备、snp标记、snp识别和应用 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN109234383A (zh) |
WO (1) | WO2020177433A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110157800A (zh) * | 2019-06-28 | 2019-08-23 | 北京和合医学诊断技术股份有限公司 | 精神类药物相关基因的检测引物组、试剂盒、体系和方法 |
CN110331214A (zh) * | 2019-07-19 | 2019-10-15 | 上海康黎医学检验所有限公司 | 一种用于指导人精神疾病用药的试剂盒及其检测方法 |
CN110511993A (zh) * | 2019-09-06 | 2019-11-29 | 江苏先声医疗器械有限公司 | 用于检测儿童药物代谢相关snp位点的引物组、应用、产品及方法 |
WO2020177433A1 (zh) * | 2018-11-07 | 2020-09-10 | 上海康黎医学检验所有限公司 | 一种用于指导人精神疾病用药的试剂盒及其检测方法 |
CN112322749A (zh) * | 2020-11-18 | 2021-02-05 | 无锡中德美联生物技术有限公司 | 同时检测str基因座和snp位点的试剂盒及其使用方法 |
CN112410409A (zh) * | 2020-12-03 | 2021-02-26 | 广东瑞昊生物技术有限公司 | 一种神经和精神类疾病基因snp位点分型优化的方法 |
CN113373211A (zh) * | 2021-05-26 | 2021-09-10 | 郑州大学 | 一种用于指导焦虑症用药的相关基因检测试剂盒及应用 |
CN117248013A (zh) * | 2023-11-07 | 2023-12-19 | 瑞因生物科技(广州)有限公司 | 一种用于人慢性精神类疾病用药药物检测的引物组、试剂盒及其应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110004222A (zh) * | 2019-04-26 | 2019-07-12 | 宁波海尔施基因科技有限公司 | 一种用于抗精神病药物用药指导的多重基因检测试剂盒及其使用方法 |
CN113322315A (zh) * | 2021-06-04 | 2021-08-31 | 上海浦东解码生命科学研究院 | 癫痫用药相关snp位点的检测产品及方法 |
CN113755578A (zh) * | 2021-09-09 | 2021-12-07 | 上海普然生物科技有限公司 | 一种用于昂丹司琼和托烷司琼代谢标志物的检测试剂盒及其检测方法和应用 |
CN116515993A (zh) * | 2023-06-25 | 2023-08-01 | 广州凯普医药科技有限公司 | 用于抑郁症用药基因检测的引物组和试剂盒 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1884528A (zh) * | 2006-06-29 | 2006-12-27 | 上海交通大学 | 与利培酮临床疗效相关的核酸序列 |
CN103667496A (zh) * | 2013-12-26 | 2014-03-26 | 江苏大学 | 人类多巴胺d2受体基因型检测芯片及其应用 |
CN105506095A (zh) * | 2015-12-30 | 2016-04-20 | 广州金域检测科技股份有限公司 | 一种检测cyp2d6基因多态性的引物与方法 |
CN105518685A (zh) * | 2013-03-12 | 2016-04-20 | 雀巢产品技术援助有限公司 | 用于为罹患抑郁症的个体选择治疗方案的测定和方法 |
CN108342466A (zh) * | 2018-05-04 | 2018-07-31 | 广州海思医疗科技有限公司 | 一种神经精神类药物相关基因的高通量测序方法及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090075827A1 (en) * | 2007-01-19 | 2009-03-19 | Queensland University Of Technology | Diagnostic methods and agents |
CN105238853A (zh) * | 2015-08-20 | 2016-01-13 | 复旦大学附属华山医院 | 一种同时测定人他克莫司作用靶点基因多态性的方法 |
CN108998515A (zh) * | 2018-08-24 | 2018-12-14 | 北京青航基因科技有限公司 | Snp组合及在制备检测药物反应相关基因的产品中的应用 |
CN109234383A (zh) * | 2018-11-07 | 2019-01-18 | 上海康黎医学检验所有限公司 | 与抗精神疾病药相关的试剂盒、目标基因及其制备、snp标记、snp识别和应用 |
CN110331214B (zh) * | 2019-07-19 | 2022-11-29 | 上海康黎医学检验所有限公司 | 一种用于指导人精神疾病用药的试剂盒及其检测方法 |
-
2018
- 2018-11-07 CN CN201811318666.6A patent/CN109234383A/zh active Pending
-
2019
- 2019-03-06 CN CN201910168662.2A patent/CN109777870B/zh active Active
- 2019-12-10 WO PCT/CN2019/124304 patent/WO2020177433A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1884528A (zh) * | 2006-06-29 | 2006-12-27 | 上海交通大学 | 与利培酮临床疗效相关的核酸序列 |
CN105518685A (zh) * | 2013-03-12 | 2016-04-20 | 雀巢产品技术援助有限公司 | 用于为罹患抑郁症的个体选择治疗方案的测定和方法 |
CN103667496A (zh) * | 2013-12-26 | 2014-03-26 | 江苏大学 | 人类多巴胺d2受体基因型检测芯片及其应用 |
CN105506095A (zh) * | 2015-12-30 | 2016-04-20 | 广州金域检测科技股份有限公司 | 一种检测cyp2d6基因多态性的引物与方法 |
CN108342466A (zh) * | 2018-05-04 | 2018-07-31 | 广州海思医疗科技有限公司 | 一种神经精神类药物相关基因的高通量测序方法及其应用 |
Non-Patent Citations (3)
Title |
---|
张玲玲,等: "Fkbp51与应激相关疾病的研究进展", 《中国比较医学杂志》 * |
汗佐拉.吾普尔,等: "抑郁症发病的神经内分泌机制研究进展", 《新疆医科大学学报》 * |
石晶,等: "男性精神***症患者吸烟与多巴胺D2受体基因多态性的关联研究", 《中国心理卫生杂志》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020177433A1 (zh) * | 2018-11-07 | 2020-09-10 | 上海康黎医学检验所有限公司 | 一种用于指导人精神疾病用药的试剂盒及其检测方法 |
CN110157800A (zh) * | 2019-06-28 | 2019-08-23 | 北京和合医学诊断技术股份有限公司 | 精神类药物相关基因的检测引物组、试剂盒、体系和方法 |
CN110157800B (zh) * | 2019-06-28 | 2022-11-04 | 北京和合医学诊断技术股份有限公司 | 精神类药物相关基因的检测引物组、试剂盒、体系和方法 |
CN110331214A (zh) * | 2019-07-19 | 2019-10-15 | 上海康黎医学检验所有限公司 | 一种用于指导人精神疾病用药的试剂盒及其检测方法 |
CN110331214B (zh) * | 2019-07-19 | 2022-11-29 | 上海康黎医学检验所有限公司 | 一种用于指导人精神疾病用药的试剂盒及其检测方法 |
CN110511993A (zh) * | 2019-09-06 | 2019-11-29 | 江苏先声医疗器械有限公司 | 用于检测儿童药物代谢相关snp位点的引物组、应用、产品及方法 |
CN110511993B (zh) * | 2019-09-06 | 2020-09-22 | 江苏先声医疗器械有限公司 | 用于检测儿童药物代谢相关snp位点的引物组、应用、产品及方法 |
CN112322749A (zh) * | 2020-11-18 | 2021-02-05 | 无锡中德美联生物技术有限公司 | 同时检测str基因座和snp位点的试剂盒及其使用方法 |
CN112322749B (zh) * | 2020-11-18 | 2023-09-19 | 无锡中德美联生物技术有限公司 | 同时检测str基因座和snp位点的试剂盒及其使用方法 |
CN112410409A (zh) * | 2020-12-03 | 2021-02-26 | 广东瑞昊生物技术有限公司 | 一种神经和精神类疾病基因snp位点分型优化的方法 |
CN113373211A (zh) * | 2021-05-26 | 2021-09-10 | 郑州大学 | 一种用于指导焦虑症用药的相关基因检测试剂盒及应用 |
CN117248013A (zh) * | 2023-11-07 | 2023-12-19 | 瑞因生物科技(广州)有限公司 | 一种用于人慢性精神类疾病用药药物检测的引物组、试剂盒及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109234383A (zh) | 2019-01-18 |
CN109777870B (zh) | 2019-10-29 |
WO2020177433A1 (zh) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109777870B (zh) | 一种用于指导人精神疾病用药的试剂盒及其检测方法 | |
Epstein et al. | Food reinforcement, the dopamine D₂ receptor genotype, and energy intake in obese and nonobese humans. | |
Niti et al. | Physical, social and productive leisure activities, cognitive decline and interaction with APOE-ε4 genotype in Chinese older adults | |
Gillen et al. | Three minutes of all-out intermittent exercise per week increases skeletal muscle oxidative capacity and improves cardiometabolic health | |
Molnar | Human variation: races, types, and ethnic groups | |
Skytthe et al. | The Danish Twin Registry in the new millennium | |
Røysamb et al. | Happiness and health: environmental and genetic contributions to the relationship between subjective well-being, perceived health, and somatic illness. | |
Steptoe et al. | Positive affect and health-related neuroendocrine, cardiovascular, and inflammatory processes | |
Strauss et al. | Severity of cardiomyopathy associated with adenine nucleotide translocator-1 deficiency correlates with mtDNA haplogroup | |
Hutchison et al. | Life cycle of toxoplasma gondii. | |
Vlahou et al. | Development of the Greek Verbal Learning Test: Reliability, construct validity, and normative standards | |
Hann et al. | Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: a longitudinal comparative study | |
Burdick et al. | DISC1 and neurocognitive function in schizophrenia | |
Pliner et al. | Perfectionism in weight‐concerned and‐unconcerned women: An experimental approach | |
Waller et al. | Core beliefs in bulimia nervosa and depression: The discriminant validity of Young's Schema Questionnaire | |
CN110331214A (zh) | 一种用于指导人精神疾病用药的试剂盒及其检测方法 | |
Atkinson et al. | Testing comprehension abilities in users of British Sign Language following CVA | |
Janszky et al. | Wine drinking is associated with increased heart rate variability in women with coronary heart disease | |
Sugahara et al. | Somatic symptoms most often associated with depression in an urban hospital medical setting in Japan | |
Mitchell et al. | Systemic absorption of cyclopentolate and adverse events after retinopathy of prematurity exams | |
Barber et al. | Prevalence and correlates of personality disorder diagnoses among ***e dependent outpatients | |
Zhao et al. | Downregulation of transketolase activity is related to inhibition of hippocampal progenitor cell proliferation induced by thiamine deficiency | |
Averill et al. | Is schizoaffective disorder a stable diagnostic category: a retrospective examination | |
Strauss | Attachment theory and psychotherapy research-Editor's introduction to a special section | |
WYATT et al. | The dimethyltryptamine-forming enzyme in blood platelets: a study in monozygotic twins discordant for schizophrenia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a kit for guiding the medication of human mental diseases and a detection method thereof Effective date of registration: 20211025 Granted publication date: 20191029 Pledgee: Industrial Bank Co.,Ltd. Shanghai Xuhui sub branch Pledgor: SHANGHAI KANGLI MEDICAL LABORATORY Co.,Ltd. Registration number: Y2021310000094 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220120 Granted publication date: 20191029 Pledgee: Industrial Bank Co.,Ltd. Shanghai Xuhui sub branch Pledgor: SHANGHAI KANGLI MEDICAL LABORATORY Co.,Ltd. Registration number: Y2021310000094 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a kit for guiding the medication of human mental diseases and a detection method thereof Effective date of registration: 20220301 Granted publication date: 20191029 Pledgee: Industrial Bank Co.,Ltd. Shanghai Xuhui sub branch Pledgor: SHANGHAI KANGLI MEDICAL LABORATORY Co.,Ltd. Registration number: Y2022310000040 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230223 Granted publication date: 20191029 Pledgee: Industrial Bank Co.,Ltd. Shanghai Xuhui sub branch Pledgor: SHANGHAI KANGLI MEDICAL LABORATORY Co.,Ltd. Registration number: Y2022310000040 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kit and detection method for guiding medication for mental disorders in humans Effective date of registration: 20230317 Granted publication date: 20191029 Pledgee: Industrial Bank Co.,Ltd. Shanghai Xuhui sub branch Pledgor: SHANGHAI KANGLI MEDICAL LABORATORY Co.,Ltd. Registration number: Y2023310000069 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231103 Granted publication date: 20191029 Pledgee: Industrial Bank Co.,Ltd. Shanghai Xuhui sub branch Pledgor: SHANGHAI KANGLI MEDICAL LABORATORY Co.,Ltd. Registration number: Y2023310000069 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A reagent kit and detection method for guiding medication for mental illness in humans Effective date of registration: 20231117 Granted publication date: 20191029 Pledgee: Industrial Bank Co.,Ltd. Shanghai Caohejing sub branch Pledgor: SHANGHAI KANGLI MEDICAL LABORATORY Co.,Ltd. Registration number: Y2023310000751 |